Abstract

Platforms for cell-free protein synthesis (CFPS) are becoming revolutionary instruments for quick vaccine and treatment development, especially in situations requiring quick response like pandemics. The molecular underpinnings of CFPS are examined in this review, which also highlights energy regeneration techniques and compares extract-based and fully synthetic systems. We go over how CFPS deals and manages the drawbacks of conventional bioreactors to produce proteins that would otherwise be impossible to obtain. The article also assesses on-demand vaccine production, including customized formulations, antigen screening, and mRNA prototyping. Particularly in areas with limited resources, CFPS is positioned for distributed, point-of-care biomanufacturing through integration with portable microfluidic equipment. In order to establish CFPS as a paradigm change for therapeutic democratization and global health preparation, we conclude by addressing important concerns of stability, storage, and regulatory adoption.